Th2 cells are essential for modulation of vascular repair by allogeneic endothelial cells by Methe, Heiko et al.
Th2 cells are essential for modulation of vascular repair by
allogeneic endothelial cells
Heiko Methe*,†, Mamoru Nanasato*,‡, Anna-Maria Spognardi*,#, Adam Groothuis*,#, and
Elazer R. Edelman*,§
* Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology,
Cambridge, Massachusetts, USA
† Department of Cardiology, University Hospital Grosshadern, Munich, Germany
‡ Cardiovascular Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan
# CBSET, Inc., Lexington, Cambridge, Massachusetts, USA
§ Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston,
Massachusetts, USA
Abstract
Background—Endothelial cells (EC) embedded within three-dimensional matrices (MEEC) when
placed in the vascular adventitia control lumenal inflammation and intimal hyperplasia. Matrix-
embedding alters endothelial immunogenicity in vitro. T helper (Th) driven host immunity is a major
impediment for of allogeneic grafts. We therefore aimed to identify if modulation of T helper balance
would affect immune compatibility and endothelial regulation of vascular repair in vivo.
Methods—Pigs (n=4/group) underwent balloon injury of both carotid arteries and were left alone
(group 1) or received perivascular implants of porcine MEEC (group 2), a 12 days course of
cyclosporine A (CsA) (group 3), or a combination of MEEC and CsA (group 4). Host immune
reactivity (EC-specific antibodies, activation of splenocytes) was analyzed after 28 and 90 days in 2
pigs/group respectively.
Results—MEEC treatment alone induced formation of EC-specific IgG1-antibodies (41±6 mean
fluorescence intensity (MFI)) and differentiation of host splenocytes into Th2, but not Th1, cytokine-
producing cells (IL-4: 242±102, IL-10: 273±114 number of spots). Concomitant CsA-therapy
reduced the frequency of IgG1-antibodies (25±2 MFI; p<0.02) and Th2-cytokine producing
splenocytes upon MEEC treatment (IL-4: 157±19, IL-10: 124±26 number of spots; p< 0.05). MEEC
significantly inhibited luminal occlusion 28 and 90 days after balloon injury compared to untreated
controls (12±7 vs. 68±14%; p<0.001) but to a lesser extent in the face of immunomodulation with
concomitant CsA-treatment (34±13%; p<0.02 vs. group 2).
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Conclusions—MEEC do not induce a significant Th1-driven immune response expected from
alloimplants, but do enhance differentiation of splenocytes into Th2-cytokine producing cells.
Reduction in this Th2 response reduces the vasoregulatory effects of allogeneic EC after injury.
INTRODUCTION
The confluent endothelium, comprised of a confluent monolayer of endothelial cells (EC)
regulates every phase of the vascular response to injury (1). Isolated EC however do not
represent the endothelium and in fact promote, rather than inhibit, thrombosis, inflammation
and proliferation of other vascular cells. The embedding of EC within three-dimensional
matrices (MEEC) preserves the confluent regulatory phenotype of EC (2–4) and allows for the
examination of endothelial regulation of vascular repair in controlled experimental settings.
MEEC are especially helpful in understanding the interaction between EC and immune
activation. Different forms of EC can be embedded within matrices and implanted in vivo
without direct contact with host immune cells or eliciting an immune response (2,5). In this
manner one can begin to examine the effects of EC on vascular repair with independent
modification of the immune state. We accomplished this by using the well-established
immunosuppressant (cyclosporine A, CsA) in an allogeneic vascular injury pig model (3,4).
CsA is not only an immune modulator in tissue and organ transplantation but its long-term use
is limited by side effects such as development of endothelial dysfunction and transplant
vasculopathy. The choice of CsA as an immunosuppressant is further amplified by the
conflicting results on direct CsA effects on EC immunogenicity in vitro (6–11) as these
influences might have a direct effect on the therapeutic use of allogeneic MEEC.
METHODS
Isolation and matrix-embedding of endothelial cells
Porcine aortic EC (PAE) were isolated from LargeWhite adult swine aortae by collagenase
treatment. PAE were grown to confluence either embedded within Gelfoam blocks (Pfizer,
NY) as previously described (2) or on polystyrene tissue culture plates (TCPS) in DMEM
supplemented with 2 mM L-glutamine, 10% FBS (HyClone, UT), 100 U/ml Penicillin G, and
100 μg/ml streptomycin (Life Technologies, Grand Island, NY). EC surface attachment and
confluence on Gelfoam matrices were demonstrated by confocal microscopy (data not shown).
Cell viability was determined by trypan blue exclusion and a LIVE/DEAD viability/
cytotoxicity kit (Molecular Probes, OR). For cell counting, blocks were washed with HBSS
(Life Technologies, Inc), digested with collagenase (1 mg/mL, type I, Worthington
Biochemical Corp) and density determined with a Neubauer’s counting chamber.
Animals, surgical procedure and tissue processing
This study conformed to the US Department of Agriculture regulations and National Research
Council guidelines and to the guidelines specified in the National Institutes of Health Guide
for Care and Use of Laboratory Animals. All animal procedures were reviewed and approved
by the local ethics committee on animal care. The study used 16 domestic LargeWhite pigs
weighing 47.4±1.2 kg and 12 to 14 weeks of age. Anesthesia was induced with Telazol (4.4
mg/kg; Wyeth, Madison, NJ), ketamine (2.2 mg/kg), glycopyrrolate (0.2 mg/mL),
acepromazine maleate (10 mg/mL), and thiopental 2.5% (0.22 mL/kg). The pigs were
intubated, anesthesia was maintained with isoflurane inhalant (0.5% to 2%) delivered through
a volume-regulated ventilator. All of the pigs underwent vascular balloon injury of both carotid
arteries as previously described.(3) The pigs were assigned to four different treatment groups
(n=4/group): vascular injury and sham surgery (neck incision) alone (group 1), with
perivascular implantation of 5×105 matrix-embedded PAE at day 0 alone (group 2), with 12
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day immunosuppressive course of CsA (10 mg/kg/d qd, Novartis Pharmaceuticals Corp., East
Hanover, NJ) begun prior to implantation and sham operation (neck incision, group 3), and a
fourth group with a 12-day immunosuppressive course of CsA and implantation of 5×105
matrix-embedded PAE. A 12 day immunosuppressive course of CsA (10 mg/kg, i.v. q.d.) has
been demonstrated effective in inducing tolerance in kidney transplantation or heart plus kidney
transplant recipient pigs across MHC class I mismatched barrier (12,13). CsA aiming levels
were 400–800 ng/ml and reached throughout the whole study period in all of the treated
animals.
All neck incisions healed well and all animals gained weight during the postoperative period.
No animal was lost during follow-up. Two animals of each group were sacrificed at 28 and 90
days respectively and angiograms quantified (baseline and at time point of euthanasia).
Angiograms were reviewed by an operator unaware of the treatment groups. Calibrating with
the outer diameter of the contrast-empty catheter, the diameter stenosis percentage was
measured and the area stenosis percentage determined.
EC Biosecretory Function
In vitro biosecretory function of PAE in Gelfoam and on TCPS with and without CsA
incubation (400 ng/ml added for the last 48 hours of culture) were compared (14,15). Total
protein production was determined by Bicinchoninic Acid protein assay-kit (Pierce). Total
glycosaminoglycans and heparan sulfate production were determined using a
dimethylmethylene blue assay before and after cell-conditioned medium treatment with
chondroitinase ABC (0.1 U/sample, Seikagaku America) for 3 hour at 37°C to eliminate
chondroitin and dermatan sulfate (16,17). Prostacyclin concentrations were determined by a
6-ketoprostaglandin F1α enzyme immunoassay system (Amersham Biosciences).
Transforming growth factor-β production was determined using standard ELISA assays
(Amersham).
Expression of proinflammatory molecules
Expression-levels of costimulatory and adhesion molecules on cultured PAE were quantified
by flow cytometry as previously described (2). In short PAE monolayers or PAE embedded in
Gelfoam were harvested after culture with or without CsA (400 ng/ml added for the last 48
hours of culture) stimulated with 100 U/mL TNF((CD54, CD80, CD86, CD106, E-selectin, P-
selectin) for 48 hours. 104 cells were analyzed by flow cytometry using a FACScalibur
instrument and CellQuest software (Becton Dickinson).
Host immune surveillance—Sera were collected serially from 0 to 90 days after vascular
injury and stored at −70°C. Splenocytes were isolated 28 and 90 days after vascular injury from
two animals/group respectively. Spleens were harvested and cut in several pieces under sterile
conditions. Clumps were immersed in solution and further dispersed by drawing and expelling
the suspension several times through a sterile syringe with a 19-G needle. The suspension was
filtered through a 200 (m mesh nylon screen to remove debris. Erythrocytes were lysed by
treatment with ACK buffer (Cambrex, Walkersville, MD) for 5 minutes at room temperature.
Remaining cells were washed twice with RPMI (containing 2 mM L-glutamine, 0.1 M HEPES,
200 U/ml Penicillin G, 200 μg/ml streptomycin, 5% heat-inactivated calf serum, Life
Technologies) and immediately used.
EC-specific antibodies
For determination of reactive antibodies specific for the implanted PAE serum was isolated at
days 0, 5, 12, 28, 56 and 90. 2×105 PAE, from the same strain as the implanted cells, were
detached from cell culture plates with 0.25% trypsin/0.04% EDTA, pelleted, washed, and
resuspended in FACS buffer (PBS, 1% FBS, 0.1% sodium azide, Sigma Chemicals, MO).
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These cells were then incubated with porcine serum from the four treatment groups for 60 min
at 4°C (diluted 1:10 in FACS buffer). After washing three times with FACS buffer, cells were
incubated with mouse anti-porcine immunoglobulin (Ig)M (clone K52 1C3), IgG1 (clone K139
3C8), or IgG2 (clone K68 Ig2; MorphoSys US Inc., NC) respectively. Following 30 min
incubation at 4°C, samples were again washed twice with cold FACS buffer, and incubated
with FITC-conjugated rabbit anti-mouse IgG (MorphoSys US Inc.) for another 30 min at 4°C.
Following two washing steps with FACS buffer, cells were fixed in 0.25 ml 1%
paraformaldehyde, and 104 cells were analyzed by flow cytometry. Control samples included
sera from naïve pigs and antibody incubation of PAE without serum to account for non-specific
binding of the secondary antibodies (background). Data are presented as mean fluorescence
intensity per PAE with background subtraction for all cells analyzed.
Enzyme-linked immunosorbent spot (ELISPOT) assay
ELISPOT assays were conducted as previously described (5,18). In short, immunospot plates
(Millipore, MA) were coated with 5 μg/ml of anti-porcine (Biosource, CA) interferon (IFN)-
γ, interleukin (IL)-2, IL-4, or IL-10 monoclonal antibodies overnight. 5×105 PAE from the
same strain as the implanted cells were placed in immunospot wells with 5×105 splenocytes
and cultured for 48 hours at 37°C/5% CO2. After washing with deionized water immunospot
wells were incubated overnight with porcine IFN-γ, IL-2, IL-4, or IL-10 monoclonal antibodies
(Biosource) followed by incubation with horseradish peroxidase–conjugated streptavidin (BD
Pharmingen, CA) for one hour. Plates were developed using 3-amino-9-ethyl-carbazole (BD
Pharmingen) and resulting spots counted on a computer-assisted enzyme-linked immunospot
image analyzer (Cellular Technology, CA). To account for background in data analysis the
number of spots in negative control wells (medium, splenocytes, or PAE alone) were subtracted
from those in responsive wells.
Calcein-Acetyoxymethyl release assay
2×104 TCPS-cultured PAE (same strain as the implanted cells) were incubated with 15 μM
calcein-acetyoxymethyl (Calcein-AM, Molecular Probes) for 40 min at 37°C with occasional
agitation. After two washes with complete medium, porcine splenocytes were added for 3 hours
at 37°C/5% CO2 at effector:target cell ratios of 50:1 to 1:1. Calcein-AM release was measured
using a Fluoroskan Ascent FL dual-scanning microplate luminofluorimeter (Thermo Electron
Corporation, TX). Specific lysis was calculated according to the formula [(test release -
spontaneous release)/(maximum release - spontaneous release)] × 100. Spontaneous release
represents calcein-AM release from target cells in medium alone, and maximum release is the
calcein-AM release from target cells lysed in medium plus 2% Triton X-100, each measured
in at least six replicate wells. Data presented within this manuscript represents effector:target
ratios of 25:1 as calcein-AM release reached a plateau at this ratio (5).
Statistical analysis
All statistical analyses were performed with JMP software (SAS Institute, USA 2002). Data
were normally distributed and expressed as mean±SD. Comparisons between 2 groups were
analyzed by Student’s t test, and comparisons between more than 2 groups were analyzed by
ANOVA. A value of p<0.05 was considered statistically significant.
RESULTS
In vitro biosecretory endothelial cell function and expression of proinflammatory molecules
are not influenced by Cyclosporine A
PAE cultured in three-dimensional Gelfoam blocks produce similar amounts of
glycosaminoglycan (2.8±0.15 versus 2.8±0.12 μg/106 cells), heparan sulfate (1.5±0.04 versus
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1.6±0.06 μg/106 cells), prostacyclin (74±5.1 versus 78±3.4 pg/106 cells), and transforming
growth factor-β (819±99 versus 864±103 pg/106 cells) as PAE grown in TCPS. Incubation of
PAE with 400 ng/ml CsA for the last 48 hours had no effect on biosecretory endothelial function
(Table).
In addition, coincubation of PAE with 400 ng/ml CsA for the last 48 hours was without effect
on basal and cytokine-induced expression of adhesion (ICAM-1, VCAM-1, E-selectin, P-
selectin), costimulatory (CD80, CD86) and MHC II molecules with lower expression levels
in MEEC throughout (Fig. 1).
Cyclosporine A limits the induction of PAE-specific IgG1 antibodies in vivo after implantation
of allogeneic matrix-embedded PAE
Circulating anti-PAE specific IgM and IgG2a levels were similar in pigs among the four
treatment groups (Fig. 2A, B). MEEC implantation induced a significant rise in PAE-specific
IgG1 antibodies from day 12 until day 56 post implantation compared to control animals
(group1, p<0.005) and animals that received a 12 day immunosuppressive course of CsA alone
(group 3, p<0.005; Fig. 2C). Concomitant CsA administration (group 4) limited the induction
of PAE-specific IgG1 antibodies (p<0.05 vs. group 2). Levels of PAE-specific IgM and
IgG2a antibodies were not affected by CsA treatment.
Cyclosporine A limits the induction of Th2 expressing splenocytes in animals treated with
perivascular implants of matrix-embedded PAE
Differentiation of splenocytes isolated form pigs from the four different treatment groups upon
in vitro stimulation with the same batch of PAE used for implantation was analyzed via
ELISPOT assay 28 and 90 days after surgery. As expected splenocytes from pigs that did not
receive PAE (group 1 and group 3) did not differentiate into T-helper cell 1 (Th1) cytokine
(IFN-γ and IL-2) or Th2 cytokine (IL-4 and IL-10) producing splenocytes.
Perivascular implantation of MEEC elicited a weak cellular immune response. Splenocytes
from pigs that were treated with allogeneic MEEC (group 2) revealed a weak non-significant
differentiation into Th1 cytokine producing splenocytes 28 days after surgery (IFN-γ: 15±4,
IL-2: 17±8 number of spots, p=0.52 vs. group 1 and group 3). Concomitant CsA treatment
(group 4) had a non-significant effect on the differentiation of splenocytes into Th1 cytokine
producing cells (IFN-γ: 12±3, IL-2: 11±1 number of spots, p=0.6 vs. group 1 and group 3). As
observed earlier, implantation of allogeneic MEEC induced a significant induction of Th2
cytokine producing splenocytes (IL-4: 237±109, IL-10: 272±119 number of spots, p<0.002 vs.
group 1 and group 3) (2). Interestingly, concomitant CsA-treatment (group 4) limited the
induction of Th2 cytokine producing splenocytes by allogeneic MEEC (IL-4: 156±21, IL-10:
121±38 number of spots, p<0.05 vs. group 2; Fig. 3A).
90 days after surgery splenocytes from treatment groups 1 and 3 lacked differentiation into
Th1 or Th2 cytokine producing splenocytes. The Th1-inducing effect of matrix-embedded PAE
observed after 28 days was not detectable 90 days after surgery (group 2: IFN-γ: 3(1, IL-2: 4
(2 number of spots; group 4: IFN-(: 2(1, IL-2: 3(2 number of spots). A weak induction of Th2
cytokine producing splenocytes was still present 90 days after surgery again with higher levels
of Th2 cytokines in the pigs that received only matrix-embedded PAE (IL-4: 78(23, IL-10: 69
(17 number of spots, p<0.02 vs. group 1 and group 3) when compared to pigs that received
matrix-embedded PAE and a concomitant 12 day course of CsA (IL-4: 47(4, IL-10: 32(7
number of spots, p<0.05 vs. group 2; Fig. 3B).
Cyclosporine A has no effect on in vitro PAE lysis by splenocytes—The ability of
host splenocytes to damage allogeneic PAE was characterized 90 days after surgery.
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Splenocytes isolated from the four treatment groups demonstrated only a weak lytic activity
to damage PAE (the same batch as used for the implantation) in vitro. Lytic activity of
splenocytes from pigs that had received matrix-embedded PAE (group 2) was 1.5-fold higher
than from sham-operated pigs (group 1) but the difference did not reach statistical significance.
CsA treatment of the pigs had no significant impact on the lytic activity of isolated splenocytes
(Fig. 4).
Cyclosporine A affects the vascular reparative effects of allogeneic matrix-embedded
endothelial cells
Analysis of carotid angiograms obtained at baseline and euthanasia revealed significant
stenosis of the arteries in control pigs without concomitant treatment (group 1, 68±14%). A
12-days course of CsA had no significant impact on the severity of luminal occlusion (group
3, 66±13%). In contrast, perivascular implants of allogeneic MEEC (group 2) had only minimal
angiographic signs of luminal occlusion (12±7%; p<0.001 vs. group 1 and group 3).
Periprocedural therapy with CsA with perivascular MEEC implants (group 4) had a middling
effect (34±13%; p<0.02 vs. group 2, p<0.005 vs. group 1 and 3; Fig. 5). There was no significant
difference between the pigs sacrificed after 28 and after 90 days.
DISCUSSION
The embedding of EC within three-dimensional collagen-based matrices not only passively
shields the cells from contact with host immune cells, but actively modulates immune reactivity
in vitro and in vivo. MEEC induce regulatory T cells, inhibit dendritic cell maturation, and shift
the balance in Th1 and Th2 cells (2,18,21).
Questions have been raised as to whether some form of immune response is important for
vascular repair and endothelial modulation of vascular injury. We used CsA as a potent and
specific immunmodulator to address these issues. Though the interference by calcineurin
inhibitors on T-cell proliferation is well-established (20) direct effects of CsA on EC remain
controversial. While some demonstrated that calcineurin inhibitors impaired endothelial
functionality - reducing prostacyclin and nitric oxide production, increasing superoxide anion,
endothelin-1 and thromboxane A2 production (10), others showed decreased expression of
costimulatory and adhesion molecules by EC (6,7,11) or even unchanged expression of
proinflammatory molecules (8,9).
We now show that commensurate with a moderate reduction in MEEC upregulation in IgG1-
antibodies and induction of Th2 cytokine-producing splenocytes, CsA also limits MEEC
inhibition of intimal hyperplasia after endothelial denudation. CsA had no effect on vascular
injury when administered alone and did no alter MEEC effects on expression of endothelial
adhesion and costimulatory molecules, on in vivo formation of EC-specific IgM, IgG2a levels,
or ex vivo lytic ability of isolated splenocytes.
There are still conflicting data on which subset of Th cells is involved in allorejection. The
polarized subsets Th1 and Th2 both develop from the same Th precursor and differentiate into
the two phenotypes via a complex development process. The dosage of antigen, strength of
signal through the T-cell receptor and costimulation influence the initiation of T helper cell
differentiation (22). Th1 and Th2 cytokines are cross-regulatory, IL-10 being an inhibitor of
the Th1 pathway and IL-12 inhibiting Th2. Evidence is accumulating that Th1 cytokines IFN-
(and IL-2 are mediators of acute and chronic graft rejection whereas Th2 cytokines, such as
IL-4 and IL-10 may have a protective role and correlate with allograft acceptance □ ADDIN
EN.CITE □ ADDIN EN.CITE.DATA (23–26).
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Our results of limited induction of Th2 cytokine producing splenocytes by allogeneic MEEC
upon concomitant CsA therapy might be mirrored by the reduction in therapeutic efficacy of
MEEC in conjunction with concomitant calcineurin treatment. There exists consensus in
different experimental settings, that Th2 cytokines are sensitive to the effect of calcineurin
antagonists. Rafiq et al. (27) as well as Dumont et al. (28) have shown decreased production
of IL-4 and IL-10 upon in vitro calcineurin incubation of T lymphocytes. The link between
qualities of host alloimmune reactivity, therapeutic efficacy of allogeneic EC to modulate
vascular repair and choice of immunosuppressant might by of significance for the choice of
immunosuppressive protocols in other transplantation settings. Our results indicate the
importance to determine not only the immune modulating effects of a given
immunosuppressant but also its effects on the function of transplanted cells and tissues.
Limitations
A series of limitations that must be appreciated in evaluating this trial are that it was performed
with a small number of animals and did not evaluate other immunosuppressive agents. Further
studies might examine the importance of reduced Th2 cytokines in allograft acceptance in
general and for the therapeutic efficacy of allogeneic MEEC in specific.
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Figure 1. Cyclosporine A is without effect on cytokine-induced endothelial expression of adhesion
and costimulatory molecules. Matrix-embedded EC reveal a significant reduced expression of
proinflammatory molecules
*p<0.05 PAE on TCPS vs. MEEC
†p<0.02 PAE on TCPS vs. MEEC
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Figure 2. Circulating PAE-specific IgG in pigs from the four treatment groups (n=4/group day 0–
28, n=2/group day 29–90). Formation of PAE-specific IgG1 antibodies by perivascular implantation
of allogeneic matrix-embedded PAE (MEEC) is limited by concomitant cyclosporine A treatment
(CsA)
A circulating PAE-specific IgM
B circulating PAE-specific IgG2a
C circulating PAE-specific IgG1
*p<0.005 vs. group 1 and group 3
†p<0.05 vs. group 4
‡p<0.02 vs. group 1 and group 3
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Figure 3. Induction of Th2-polarized splenocytes is reduced in pigs after vascular injury and
treatment with perivascular implants of allogeneic matrix-embedded PAE (MEEC) with
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concomitant cyclosporine A treatment (CsA). ELISPOT assay was performed 28 (A) and 90 days
(B) after balloon injury
*p<0.002 vs. group 1 and group 3
†p<0.05 vs. group 2
‡p<0.02 vs. group 1 and group 3
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Figure 4. Splenocytes isolated from the four different treatment groups display no significant
difference in in vitro lysis of allogeneic PAE. 104 PAE were labeled with calcein and incubated with
5×105 splenocytes isolated after 28 and 90 days, respectively
MEEC: matrix-embedded PAE, CsA: cyclosporine A
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Figure 5. Concomitant cyclosporine A treatment (CsA) modulates the ability of perivascular
implanted matrix embedded PAE (MEEC) to influence vascular repair after balloon injury
A Representative angiograms of carotid arteries before (left) and 90 days (right) after balloon
injury in the four treatment groups (sham; matrix-embedded PAE, MEEC; cyclosporine A
alone, CsA; matrix-embedded PAE with CsA, MEEC+CsA).
*carotid artery
#endotracheal tube
B Degree of stenosis (%) after balloon injury of both carotid arteries in the four pig treatment
groups. Symbols: individual data, dashed lines: mean±SD
*p<0.001 vs. group 1 and group 3
†p<0.02 vs. group 2
‡p<0.005 vs. group 1 and group 3
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TABLE
Cyclosporine A is without effect on biosecretion of porcine aortic endothelial cells in vitro
PAE MEEC
PAE MEEC 400 ng/ml
CsA PAE TCPS
PAE TCPS 400 ng/ml
CsA
GAG [μg/106 cells] 2.8±0.15 2.6±0.2 2.8±0.12 2.7±0.17
HS [μg/106 cells] 1.5±0.04 1.5±0.12 1.6±0.06 1.5±0.08
prostacyclin [pg/106 cells] 74±5.1 69±6.4 78±3.4 75±7.1
TGF-β [pg/106 cells] 819±99 794±131 864±103 839±167
PAE: porcine aortic endothelial cells, MEE: matrix-embedded, TCPS: tissue culture polystyrene plates, GAG: glycosaminoglycans, HS: heparan
sulfate, TGF-β: transforming growth factor-β CsA: cyclosporine A
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